Company Profile
Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows:
- dialysis treatment (46.8%; Fresenius Medical Care): sales of equipment for hemodialysis, pediatric dialysis, peritoneal dialysis, dialysis services, etc.;
- hospital administration and engineering (34.2%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.;
- perfusion and clinical nutrition (19%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc.
Net sales are distributed geographically as follows: Europe (45%), North America (38.3%), Asia/Pacific (10.5%), Latin America (4.9%) and Africa (1.3%).
- dialysis treatment (46.8%; Fresenius Medical Care): sales of equipment for hemodialysis, pediatric dialysis, peritoneal dialysis, dialysis services, etc.;
- hospital administration and engineering (34.2%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.;
- perfusion and clinical nutrition (19%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc.
Net sales are distributed geographically as follows: Europe (45%), North America (38.3%), Asia/Pacific (10.5%), Latin America (4.9%) and Africa (1.3%).
Source: Cofisem - Last Update: 2023-05-18
Key Executives
| Chairman of the Management Board | Michael Sen |
| Member of the Management Board | Sebastian Biedenkopf |
| Member of the Management Board | Francesco De Meo |
| Member of the Management Board | Ernst Wastler |
| Chief Financial Officer | Sara Hennicken |
| Human Resources Director | Sebastian Biedenkopf |
| General Counsel | Sebastian Biedenkopf |
| Investor Relations Director | Markus Georgi |
| VP, Communication | Matthias Link |
Source: Cofisem - Last Update: 2023-05-02
Key Figures
| Millenium | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Cost of financial indebtedness net | 507,000 | 506,000 | 659,000 | 719,000 | 587,000 |
| Operating income | 3,321,000 | 4,158,000 | 4,385,000 | 4,631,000 | 5,251,000 |
| Net income | 2,117,000 | 2,819,000 | 2,823,000 | 3,029,000 | 3,714,000 |
| Income from ordinary activities | 40,840,000 | 37,520,000 | 36,277,000 | 35,409,000 | 33,530,000 |
| Net profit from discontinued activities | |||||
| Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
| Net sales | 40,840,000 | 37,520,000 | 36,277,000 | 35,409,000 | 33,530,000 |
| Currency & Unit | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands |
| Net income (Group share) | 1,372,000 | 1,818,000 | 1,707,000 | 1,883,000 | 2,027,000 |
| Equity-accounted companies contribution to income | |||||
| Fiscal year end | 12.22 | 12.21 | 12.2 | 12.19 | 12.18 |
| Account Standards |
Source: Cofisem - Last Update: 2023-05-18
Shareholder information
| Institutional shareholders | 61 % |
| Else Kröner-Fresenius Foundation | 27 % |
| Other shareholders | 12 % |
Source: Cofisem - Last Update: 2023-05-18
Address
Fresenius SE & Co. KGaA
Else-Kröner-Strasse 1
DE-61352 Bad Homburg vor der Höhe, Hessen
Germany
Phone number: +49 (0) 6172 608 0
https://www.fresenius.com
Source: Cofisem - Last Update: 2023-05-18
Please contact MyQuestion.Italy@euronext.com for Company Profile support.